RS51546B - Pyrazole derivatives as protein kinase modulators - Google Patents
Pyrazole derivatives as protein kinase modulatorsInfo
- Publication number
- RS51546B RS51546B RSP-2010/0532A RSP20100532A RS51546B RS 51546 B RS51546 B RS 51546B RS P20100532 A RSP20100532 A RS P20100532A RS 51546 B RS51546 B RS 51546B
- Authority
- RS
- Serbia
- Prior art keywords
- group
- heteroaryl
- alkoxy
- phenyl
- hydrocarbyl
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Jedinjenje formule (I):ili njegova so, solvat, tautomer ili N-oksid;u kome, A je zasićena ugljovodonična linker grupa koja sadrži od 1 do 7 atoma ugljenika, pri čemu linker grupa ima maksimalnu dužinu lanca od 5 atoma koji se pruža između R1 i NR2R3 i maksimalnu dužinu lanca od 4 atoma koji se pruža između E i NR2R3, pri čemu jedan od atoma ugljenika u linker grupi mogu biti izborno zamenjeni atomom kiseonika ili azota; i pri čemu atomi ugljenika linker grupe A mogu izborno da nose jedan ili više supstituenata koji su izabrani od okso, fluora i hidroksida, uz uslov da se hidroksi grupa kada je prisutna ne nalazi na atomu ugljenika α u odnosu na NR2R3 grupu i uz uslov da se okso grupa kada je prisutna nalazi na atomu ugljenika α u odnosu na NR2R3 grupu;E je monociklična, biciklična karbociklična ili heterociklična grupa u kojoj, E je nesupstituisan ili ima do 4 supstituenta R8 izabrana iz grupe koju čine hidroksi, okso (kada je E nearomatičan), hlor, brom, trifluorometil, cijano, C1-4 hidrokarbiloksi i C1-4 hidrokarbil izborno supstituisan sa C1-2 alkoksi ili hidroksil;R1 je aril ili heteroaril grupa koja je nesupstituisana ili nosi jedan ili više supstituenata koji su izabrani iz grupe koju čine hidroksi; C1-4 aciloksi; fluor; hlor; brom; trifluorometil; cijano; CONH2; nitro; C1-4 hidrokarbiloksi i C1-4 hidrokarbil, pri čemu je svaki od njih izborno supstituisan sa C1-2 alkoksi, karboksi ili hidroksi; C1-4 acilamino; benzoilamino; pirolidinokarbonil; piperidinokarbonil; morfolinokarbonil; piperazinokarbonil; pet i šesto-člane heteroaril i heteroariloksi grupe koje sadrže jedan ili dva heteroatoma izabrana od N, O i S; fenil; fenil-C1-4alkil; fenil- C1-4 alkoksi; heteroaril- C1-4 alkil; heteroaril- C1-4 alkoksi i fenoksi, pri čemu su svaka od heteroaril, heteroariloksi, fenil, fenil- C1-4 alkil, fenil- C1-4 alkoksi, heteroaril-C1-4 alkil, heteroaril-C1-4 alkoksi i fenoksi grupa izborno supstituisana sa 1, 2 ili 3 supstituenata koji su izabrani iz grupe koju čine C1-2 aciloksi, fluor, hlor, brom, trifluorometil, cijano, CONH2, C1-2 hidrokarbiloksi i C1-2 hidrokarbil, gde je svaki od njih izborno supstituisan sa metoksi ili hidroksil;R2 i R3 nezabvisno su izabrani iz grupe koju čine vodonik, C1-4 hidrokarbil i C1-4 acil, pri čemu su hidrokarbil i acil grupe izborno supstituisane sa jednim ili više supstituenata koji su izabrani iz grupe koju čine fluor, hidroksi, amino, metilamino, dimetilamino i metoksi;ili R2 i R3 zajedno sa atomom azota za koji su vezani formiraju cikličnu grupu koja je izabrana od imidazol grupe i zasićene monociklične heterociklične grupe koja ima 4-7 članova u prstenu i izborno sadrži drugi heteroatom kao član prstena izabran od O i N;ili jedan od RCompound of Formula (I): or a salt, solvate, tautomer or N-oxide thereof, wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, wherein the linker group has a maximum chain length of 5 atoms which is provided between R1 and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, wherein one of the carbon atoms in the linker group may be optionally replaced by an oxygen or nitrogen atom; and wherein the linker group A carbon atoms may optionally carry one or more substituents selected from oxo, fluorine and hydroxide, provided that the hydroxy group when present is not present on the carbon atom α relative to the NR2R3 group and provided that the oxo group when present is on the carbon atom α relative to the NR2R3 group; E is a monocyclic, bicyclic carbocyclic or heterocyclic group in which, E is unsubstituted or has up to 4 substituents R8 selected from the group consisting of hydroxy, oxo (when E non-aromatic), chlorine, bromine, trifluoromethyl, cyano, C1-4 hydrocarbloxy and C1-4 hydrocarbyl optionally substituted with C1-2 alkoxy or hydroxyl; R1 is an aryl or heteroaryl group which is unsubstituted or carries one or more substituents selected from the group consisting of hydroxy; C1-4 acyloxy; fluorine; chlorine; bromine; trifluoromethyl; cyano; CONH2; nitro; C1-4 hydrocarbloxy and C1-4 hydrocarbyl, each of which is optionally substituted with C1-2 alkoxy, carboxy or hydroxy; C1-4 acylamino; benzoylamino; pyrrolidinocarbonyl; piperidinocarbonyl; morpholinocarbonyl; piperazinocarbonyl; five and six-membered heteroaryl and heteroaryloxy groups containing one or two heteroatoms selected from N, O and S; phenyl; phenyl-C 1-4 alkyl; phenyl-C 1-4 alkoxy; heteroaryl-C 1-4 alkyl; heteroaryl-C 1-4 alkoxy and phenoxy, each of which is heteroaryl, heteroaryloxy, phenyl, phenyl-C 1-4 alkyl, phenyl-C 1-4 alkoxy, heteroaryl-C 1-4 alkyl, heteroaryl-C 1-4 alkoxy and phenoxy group optionally substituted with 1, 2 or 3 substituents selected from the group consisting of C1-2 acyloxy, fluorine, chlorine, bromine, trifluoromethyl, cyano, CONH2, C1-2 hydrocarbloxy and C1-2 hydrocarbyl, each of which is optionally substituted with methoxy or hydroxyl; R2 and R3 are independently selected from the group consisting of hydrogen, C1-4 hydrocarbyl and C1-4 acyl, wherein the hydrocarbyl and acyl groups are optionally substituted with one or more substituents selected from the group consisting of fluorine, hydroxy, amino, methylamino, dimethylamino and methoxy; or R2 and R3 together with the nitrogen atom to which they are attached form a cyclic group selected from imidazole group and a saturated monocyclic heterocyclic group having 4-7 ring members and optionally containing another heteroatom as ring member selected by O and N; or one of R
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53219903P | 2003-12-23 | 2003-12-23 | |
GB0329617A GB0329617D0 (en) | 2003-12-23 | 2003-12-23 | Pharmaceutical compounds |
US57784304P | 2004-06-08 | 2004-06-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
RS51546B true RS51546B (en) | 2011-06-30 |
Family
ID=30776233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RSP-2010/0532A RS51546B (en) | 2003-12-23 | 2004-12-23 | Pyrazole derivatives as protein kinase modulators |
Country Status (11)
Country | Link |
---|---|
CN (1) | CN1922148B (en) |
AT (1) | ATE483689T1 (en) |
DE (1) | DE602004029501D1 (en) |
DK (1) | DK1706385T3 (en) |
GB (1) | GB0329617D0 (en) |
ME (1) | ME01934B (en) |
PT (1) | PT1706385E (en) |
RS (1) | RS51546B (en) |
SI (1) | SI1706385T1 (en) |
UA (1) | UA90461C2 (en) |
ZA (1) | ZA200605127B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0704932D0 (en) * | 2007-03-14 | 2007-04-25 | Astex Therapeutics Ltd | Pharmaceutical compounds |
CN108339121A (en) * | 2017-01-25 | 2018-07-31 | 苏州大学 | Application of protein kinase A inhibitor in preparation of medicines for treating diseases related to platelet increase |
CN111056990B (en) * | 2019-12-16 | 2022-06-17 | 爱斯特(成都)生物制药股份有限公司 | Preparation method for synthesizing 1-tert-butyloxycarbonyl-4- (4-carboxyphenyl) piperidine |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9804734D0 (en) * | 1998-03-05 | 1998-04-29 | Pfizer Ltd | Compounds |
CN1193026C (en) * | 1999-07-30 | 2005-03-16 | 艾博特股份有限两合公司 | Z-pyrazoline-5-ones |
-
2003
- 2003-12-23 GB GB0329617A patent/GB0329617D0/en not_active Ceased
-
2004
- 2004-12-23 UA UAA200608166A patent/UA90461C2/en unknown
- 2004-12-23 SI SI200431571T patent/SI1706385T1/en unknown
- 2004-12-23 CN CN2004800420375A patent/CN1922148B/en not_active Expired - Fee Related
- 2004-12-23 AT AT04806258T patent/ATE483689T1/en active
- 2004-12-23 PT PT04806258T patent/PT1706385E/en unknown
- 2004-12-23 DK DK04806258.2T patent/DK1706385T3/en active
- 2004-12-23 RS RSP-2010/0532A patent/RS51546B/en unknown
- 2004-12-23 DE DE602004029501T patent/DE602004029501D1/en active Active
- 2004-12-23 ME MEP-2010-532A patent/ME01934B/en unknown
-
2006
- 2006-06-21 ZA ZA200605127A patent/ZA200605127B/en unknown
Also Published As
Publication number | Publication date |
---|---|
DE602004029501D1 (en) | 2010-11-18 |
CN1922148A (en) | 2007-02-28 |
UA90461C2 (en) | 2010-05-11 |
ME01934B (en) | 2011-06-30 |
CN1922148B (en) | 2012-03-21 |
PT1706385E (en) | 2010-12-22 |
ZA200605127B (en) | 2010-07-28 |
ATE483689T1 (en) | 2010-10-15 |
SI1706385T1 (en) | 2011-01-31 |
GB0329617D0 (en) | 2004-01-28 |
DK1706385T3 (en) | 2011-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS54260B1 (en) | Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease | |
RS51780B (en) | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors | |
RS53688B1 (en) | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | |
CL2012000999A1 (en) | Substituted pyrazolospiroketone derivative compounds, acetyl-coa carboxylase inhibitors; pharmaceutical composition comprising them; use to treat or delay the progression or onset of type 2 diabetes, non-alcoholic fatty liver (hgna), or hepatic insulin resistance. | |
RS53641B1 (en) | Pyrazolo pyridine derivatives as nadph oxidase inhibitors | |
RS52061B (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
AR049578A1 (en) | HYDANTOIN DERIVATIVES, OBTAINING PROCESSES AND PHARMACEUTICAL COMPOSITIONS | |
HRP20070584T3 (en) | Aminoquinoline derivatives and their use as adenosine a3 ligands | |
WO2003106428A8 (en) | Arylsulphonamide derivatives and use thereof as b1 bradykinin receptor antagonists | |
CO6231028A2 (en) | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF PROTEIN QUINASA | |
AR067757A1 (en) | IMIDAZO DERIVATIVES [4,5-C] PIRIDIN-2-ONA, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCEDURE FOR THE PREPARATION AND USE OF THE SAME AS ANTIVIRAL AGENTS. | |
RS53142B (en) | Compounds having crth2 antagonist activity | |
BRPI0506817A (en) | selective kinase inhibitors | |
HRP20090270B1 (en) | Derivates of dioxane-2-alkyl carbamates, preparation method thereof and application of same in therapeutics | |
MX344276B (en) | Novel piperidine compound or salt thereof. | |
RS52679B (en) | Renin inhibitors | |
RS51919B (en) | Derivatives of benzothiazepine and their use as modulators of ampa and nmda receptors | |
NI200900181A (en) | NEW NITROGENATED HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIAL DRUGS. | |
RS51193B (en) | Hydantoin derivatives useful as metalloproteinase inhibitors | |
JP2006523698A5 (en) | ||
RS51320B (en) | Imidazoquinoline derivatives as adenosine a3 receptor ligands | |
RS51546B (en) | Pyrazole derivatives as protein kinase modulators | |
HRP20030610B1 (en) | Process for the preparation of mesylates of piperazine derivatives | |
AR057558A1 (en) | CINOLINCARBOXAMIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITION | |
RS53011B (en) | Aminopyrazole triazolothiadiazole inhibitors of c-met protein kinase |